國家衛生研究院 NHRI:Item 3990099045/15433

NHRI > National Center for Geriatrics and Welfare Research > Chen-Yu Wang > Conference Papers/Meeting Abstract > Item 3990099045/15433

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/15433

Title:	Long dosing intervals of antiosteoporosis medications decrease national fracture risk: A nationwide population-based cohort study
Authors:	Fu, SH;Yen, HK;Yang, RS;Lee, CC;Li, CY;Wang, CY
Contributors:	National Center for Geriatrics and Welfare Research
Abstract:	Objective: We hypothesized that long dosing interval antiosteoporosis medications (AOMs), mainly those delivered parenterally, will guarantee higher adherence and persistence, which could help reduce fracture risk. The aim of this research was to evaluate the relationship between different dosing intervals of AOM and the subsequent fracture risk among patients newly initiated AOM therapies. Methods: It is a nationwide population-based cohort study based on Taiwan’s National Health Insurance Research Database. Osteoporosis patients with age C 50 who newly initiated AOM during 2008–2018 (n = 336,229) were included. We categorized AOMs into short dosing intervals (oral AOMs) or long dosing intervals (parenteral AOMs). The adherence and persistence of treatment by medication possession ratio (MPR) and subsequent fracture after treatment for 3 years were measured. Results: Among patients who initiated parenteral AOMs, the percentage of patients with high adherence (MPR C 75%) increased from 33% in 2008 to 69% in 2018. However, among patients who initiated oral AOMs, the percentage of high adherence remained stable (30%) between 2008–2018. The use of parenteral AOMs increased from 1% in 2008 to 62% in 2018. At the same time, the percentage of high adherence of those initiated AOMs signiﬁcantly increased from 34% in 2008 to 61% in 2018. The risk of subsequent fracture decreased signiﬁcantly between 2008–2018 after controlling for all potential confounders (hazard ratio = 0.85, 95% CI = 0.81–0.89). Conclusion: AOMs with long dosing intervals not only increased adherence and persistence but also decreased the subsequent fracture risk at a nationwide scale.
Date:	2023-07-21
Relation:	Aging Clinical and Experimental Research. 2023 Jul 21;35:S143.
Link to:	http://dx.doi.org/10.1007/s40520-023-02442-7
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1594-0667&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:001058500201016
Appears in Collections:	[Chen-Yu Wang] Conference Papers/Meeting Abstract

Files in This Item:

File	Size	Format
ISI001058500201016.pdf	70Kb	Adobe PDF	39	View/Open

Loading...